Clinical Research in Cardiology

, Volume 102, Issue 9, pp 637–644

Outcomes of correcting hyponatremia in patients with myocardial infarction

  • Waqas Qureshi
  • Syed Hassan
  • Fatima Khalid
  • Mohamed Faher Almahmoud
  • Bhavik Shah
  • Ra’ad Tashman
  • Nikhil Ambulgekar
  • Mostafa El-Refai
  • Chetan Mittal
  • Zaid Alirhayim
Original Paper



Hyponatremia has significant prognostic implications in patients with heart, failure. However, little data are available regarding its significance in patients presenting with myocardial infarction. In addition, it is not known if correction of hyponatremia impacts outcomes in these patients. The aim of this study was to evaluate the prognostic value of hyponatremia in patients with myocardial infarction and the effect of its correction on all-cause mortality.


Patients with the discharge diagnosis of myocardial infarction at our institution between 2000 and 2010 with serum sodium levels measured within 24 h of admission were included in this retrospective analysis. Multivariate analysis was used to determine the predictors of all-cause mortality. Cox proportional hazard model was applied to determine the adjusted survival.


A total of 11,562 patients (67.15 ± 14.6 years, males 56.3 %) were included in the analysis. There were a total of 1,535 (13.3 %) deaths within mean follow-up duration of 5.5 ± 3.3 years. There were 425 (27.9 %) deaths in patients with corrected hyponatremia and 155 (55.3 %) deaths in persistent hyponatremia patients. Multivariate analysis indicated that corrected hyponatremia and persistent hyponatremia were independent predictors of all cause mortality (p < 0.0001). When analyzing short-term (30 days) and long-term mortality, corrected hyponatremia group did not have associated long term mortality. Various methods to correct hyponatremia were also analyzed and use of vaptans was associated with decrease in mortality in patients with hyponatremia from 115 to 125 (HR 0.45; 95 % CI 0.26–0.78, p = 0.005).


Our analysis showed that corrected and persistent hyponatremia in patients presenting with myocardial infarction is a predictor of all-cause mortality, major adverse cardiac events and heart failure related 30 day rehospitalization. In certain cases, correction of hyponatremia may actually improve survival of the patients.


Myocardial infarction  Hyponatremia  Vaptan  Outcomes 


  1. 1.
    Anderson RJ, Chung HM, Kluge R, Schrier RW (1985) Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 102:164–168PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen JP (2006) Cost-effectiveness and resource allocation. J Am Med Assoc 295:2723 author reply -4CrossRefGoogle Scholar
  3. 3.
    Goldberg A, Hammerman H, Petcherski S et al. (2006) Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 166:781–786PubMedCrossRefGoogle Scholar
  4. 4.
    Waikar SS, Mount DB, Curhan GC (2009) Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 122:857–865PubMedCrossRefGoogle Scholar
  5. 5.
    Klein L, O’Connor CM, Leimberger JD et al (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111:2454–2460PubMedCrossRefGoogle Scholar
  6. 6.
    Gheorghiade M, Abraham WT, Albert NM et al (2007) Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 28:980–988PubMedCrossRefGoogle Scholar
  7. 7.
    Movafagh S, Cleemann L, Morad M (2011) Regulation of cardiac Ca(2+) channel by extracellular Na(+). Cell Calcium 49:162–173PubMedCrossRefGoogle Scholar
  8. 8.
    Havranek S, Belohlavek J, Skulec R, Kovarnik T, Dytrych V, Linhart A (2011) Long-term prognostic impact of hyponatremia in the ST-elevation myocardial infarction. Scand J Clin Lab Invest 71:38–44PubMedCrossRefGoogle Scholar
  9. 9.
    Klopotowski M, Kruk M, Przyluski J et al (2009) Sodium level on admission and in-hospital outcomes of STEMI patients treated with primary angioplasty: the ANIN Myocardial Infarction Registry. Med Sci Monit Int Med J Exp Clin Res 15:CR477–CR483Google Scholar
  10. 10.
    Dargie HJ, Cleland JG, Leckie BJ, Inglis CG, East BW, Ford I (1987) Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation 75:IV98–IV107PubMedGoogle Scholar
  11. 11.
    Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z (1991) Cardiac conduction defects associated with hyponatremia. Clin Cardiol 14:165–168PubMedCrossRefGoogle Scholar
  12. 12.
    AbouEzzeddine O, Prasad A (2010) Apical ballooning syndrome precipitated by hyponatremia. Int J Cardiol 145:e26–e29PubMedCrossRefGoogle Scholar
  13. 13.
    Graham LN, Smith PA, Stoker JB, Mackintosh AF, Mary DA (2002) Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation 106:793–797PubMedCrossRefGoogle Scholar
  14. 14.
    Schaller MD, Nussberger J, Feihl F et al (1987) Clinical and hemodynamic correlates of elevated plasma arginine vasopressin after acute myocardial infarction. Am J Cardiol 60:1178–1180PubMedCrossRefGoogle Scholar
  15. 15.
    Sigurdsson A, Held P, Swedberg K (1993) Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126:1068–1076PubMedCrossRefGoogle Scholar
  16. 16.
    Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341:577–585PubMedCrossRefGoogle Scholar
  17. 17.
    Schrier RW, Berl T (1973) Mechanism of effect of alpha adrenergic stimulation with norepinephrine on renal water excretion. J Clin Investig 52:502–511PubMedCrossRefGoogle Scholar
  18. 18.
    Xu DL, Martin PY, Ohara M et al (1997) Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Investig 99:1500–1505PubMedCrossRefGoogle Scholar
  19. 19.
    Funayama H, Nakamura T, Saito T et al (2004) Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 66:1387–1392PubMedCrossRefGoogle Scholar
  20. 20.
    Sutton MG, Sharpe N (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101:2981–2988PubMedCrossRefGoogle Scholar
  21. 21.
    Yang XD, Zhao LY, Zheng QS, Li X (2003) Effects of arginine vasopressin on growth of rat cardiac fibroblasts: role of V1 receptor. J Cardiovasc Pharmacol 42:132–135PubMedCrossRefGoogle Scholar
  22. 22.
    Wada K, Fujimori A, Matsukawa U et al (2005) Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 507:145–151PubMedCrossRefGoogle Scholar
  23. 23.
    Schrier RW, Gross P, Gheorghiade M et al (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099–2112PubMedCrossRefGoogle Scholar
  24. 24.
    Holmes CL, Landry DW, Granton JT (2004) Science review: vasopressin and the cardiovascular system part 2—clinical physiology. Crit Care 8:15–23PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Waqas Qureshi
    • 1
  • Syed Hassan
    • 1
  • Fatima Khalid
    • 1
  • Mohamed Faher Almahmoud
    • 2
  • Bhavik Shah
    • 1
  • Ra’ad Tashman
    • 1
  • Nikhil Ambulgekar
    • 1
  • Mostafa El-Refai
    • 1
  • Chetan Mittal
    • 1
  • Zaid Alirhayim
    • 1
  1. 1.Department of Internal MedicineHenry Ford Health Systems/Wayne State University School of MedicineDetroitUSA
  2. 2.Department of Internal MedicineSt. John’s HospitalGross PointeUSA

Personalised recommendations